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ABSTRACT 
Background: Studies of istradefylline (KW6002), an adenosine A2A-receptor 
antagonist, have provided evidence of its efficacy as a nondopaminergic anti- 
parkinsonian drug. Antiparkinsonian drugs have also had efficacy in treating 
restless legs syndrome (RLS). 
Objectives: The aims of this study were to assess the effectiveness and 
tolerability of istradefylline in the treatment of RLS. 
Methods: This was a single-center, multiparametric, prospective trial of 
istradefylline as a treatment for moderate to severe idiopathic RLS. It was con- 
ducted at the Shands/Jacksonville Sl ep Disorders Center, University of Florida, 
Jacksonville, Florida, from March 2003 to October 2003. Patients received a 
single PO 80-mg dose QD of istradefylline in the late afternoon or early eve- 
ning for 6 weeks. Appropriate tolerability evaluations (ie, vital assessments, 
physical examination, clinical laboratory tests, and electrocardiogram) were 
performed at screening, while on study drug, and after withdrawal of study 
drug. 
Results: Fifteen participants (mean [SD] age, 61 [7.1] years; range, 50-69 years) 
were screened for enrollment. The mean duration of RLS was 18 years. Of the 
15 potential patients, 6 did not meet entry criteria, 2 withdrew consent, 1 had 
not completed baseline procedures at the time of study suspension, and 1 was 
excluded for administrative r asons. Therefore, a total of 5 patients received 
the study drug. Of these, 3 (60%) patients responded favorably to istradefylline 
treatment. Improvement in the periodic limb movement index was observed in 
3 patients compared with baseline (patients 2, 4, and 5 [index score: 6, 4, 9 vs 
50, 35, 18, respectively]). Improvement in the International RLS Rating Scale 
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scores was observed in 3 patients compared with baseline (patients 2, 4, and 5 
[index score: 7, 23, 9 vs 35, 25, 20, respectively]). There was a return to baseline 
severity in 2 of the 3 patients after withdrawal of study drug. Improvement in
RLS symptoms was observed in 3 patients treated with istradefylline for 
6 weeks. A clinical worsening of baseline insomnia was observed in 2 patients. 
Conclusions: Although we could not definitively conclude a beneficial effect 
based on this small exploratory trial, we found the data to be encouraging. The 
study drug was well tolerated. Further study of this compound in the treatment 
of RLS is justified. (Curt Ther Res Clin Exp. 2007;68:349-359) Copyright © 2007 
Excerpta Medica, Inc. 
Key words: restless legs syndrome, periodic limb movements, polysomnog- 
raphy, istradefylline, adenosine antagonists, dopaminergic agonist, KW6002. 
INTRODUCTION 
Although the mechanism underlying restless legs syndrome (RLS) may be 
distinct from that of Parkinson's disease (PD), both conditions respond to 
dopaminergic stimulation. 1-3 Dopaminergic drugs are currently considered the 
treatment ofchoice for RLS. 1,2 However, not all patients with RLS sustain a long- 
term response with dopaminergic drugs. 3A form of pharmacologic tolerance, 
augmentation, has been observed where symptoms fail to respond, typically 
becoming manifest earlier in the day. Augmentation, however, has only been 
observed in the context of dopaminergic treatment. 3 In addition, dopaminer- 
gic drugs have been associated with a variety of toxicities, including daytime 
sedation, gastrointestinal adverse vents (AEs), and orthostatic hypotension. 2 
Therefore, it is critical to explore the efficacy and effectiveness of nondopamin- 
ergic agents in the treatment of RLS. 
A potential nondopaminergic RLS treatment is istradefylline (KW6002, Kyowa 
Pharmaceuticals, Princeton, New Jersey), an adenosine A2A-receptor antagonist. 4 
Similar to dopaminergic drugs, istradefylline exhibits an ameliorating effect on 
the symptoms of PD. 5-9 In PD, depletion of striatal dopamine results in ex- 
cessive activation of pathways transmitting 7-aminobutyric a id that are medi- 
ated by adenosine A2A receptors. This has the effect of reducing inhibitory 
outflow from the globus pallidus to the subthalamus. The striatopallidal (in- 
direct) pathway then becomes overactive. In this instance, adenosine A2A- 
receptor antagonists, independent of dopamine, would be expected to restore 
the pathway to its normal condition by suppressing the current state of pallidal 
disinhibition. 1° 
Istradefylline is highly selective for adenosine A2A receptors. Because ade- 
nosine A2A receptors in the central nervous ystem are located primarily in the 
striatum, istradefylline might be associated with fewer dopaminergic AEs com- 
pared with levodopa or dopamine agonists. Istradefylline has been reported to 
ameliorate parkinsonism in experimental models 6,7,9 and in Phase II studies in 
patients with PD who were experiencing end-of-dose wearing off and peak-dose 
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dyskinesias as a result of motor complications associated with levodopa 
treatment. 4,8 In an experimental model with rats, istradefylline mimicked the ac- 
tivity of other anti-RLS agents, which was thought o predict reatment response 
for RLS in humans. 6 These data suggest hat an adenosine A2A-receptor antago- 
nist, such as istradefylline, might have therapeutic activity in RLS. Effective 
doses in humans have ranged from 20 to 80 mg administered QD. 11 
The primary objective of this study was to assess the effectiveness of istradefyl- 
line 80 mg (KW6002) in patients with RLS after 3 and 6 weeks of treatment. The 
secondary objective was to accumulate data regarding the tolerability of istradefyl- 
line in patients with RLS. 
A literature search was performed using Ovid and MEDLINE for relevant 
English-language articles published from 1987 to 2007 using the following key 
terms: restless legs syndrome, adenosine antagonists, istradefylline, and KW6002. 
A search of the l iterature did not find studies investigating adenosine antago- 
nists in RLS. 
PATIENTS AND METHODS 
Patients 
This single-center, multiparametric, prospective trial conducted at the Shands/ 
Jacksonville Sleep Disorders Center, University of Florida, Jacksonville, Florida, 
from March 2003 to October 2003. it was approved by the Western institutional 
Review Board. Written informed consent was obtained from all part ic ipants 
before study entry. The study was performed in accordance with the principles 
of the Declaration of Helsinki 12 and the guidelines on Good Clinical Practice. 13 
Prospective participants were recruited through a third-party RLS patient 
support  organization and also through a local newspaper advert isement describ- 
ing the study, the disorder, and the entry criteria. Adults aged >18 years with 
idiopathic RLS according to the International RLS Study Group 14 were eligible for 
inclusion. Additional inclusion criteria were as follows: patients had to be experi- 
encing at least moderately severe RLS as classified by the International RLS 
rating scale 15 (IRLSRS) as a score >15 (0 = none; 1-10 = mild; 11-20 = moderate; 
21-30 = severe; 31-40 = very severe) and RLS symptoms had to be present for 
>3 days each week in the 3 months before study entry. Patients also had to expe- 
rience an average periodic limb movement index (PLMI) 16 <20 during baseline 
assessments. The PLMI is the record of the number of leg or arm movements 
during each hour of sleep. The PLMI scale indicator is as follows: >5 per hour = 
mildly abnormal; >20 = moderately severe; and >50 = severe. Patients were 
excluded for the following reasons: pregnancy, current breastfeeding, or not 
using adequate contraception; diagnosed with diabetes or significant renal, 
hepatic, gastrointestinal, pulmonary, endocrine, or sleep disorders (unrelated to 
RLS); active depression, psychosis, dementia, or a history of neuroleptic malig- 
nant syndrome; or if receiving cytochrome P450 3A4 inhibitors. Additionally, 
because undiagnosed sleep apnea might have confounded the clinical evaluation 
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of RLS, baseline polysomnography was used as an objective means for determin- 
ing the presence of sleep apnea. The apnea-hypopnea index (AHI) 17 represents 
the average number of apnea and hypopnea events that occur per hour during 
polysomnographically determined sleep. Because an AHI of >15 confirms the 
diagnosis of sleep apnea, patients with an AHI score of >15 were excluded from 
the study. 
At study entry, patient history was assessed and recorded. Additionally, 
serum [3-human chorionic gonadotropin concentration and complete blood 
count were assessed for secondary causes of RLS (eg, pregnancy and renal 
failure). We did not screen for iron deficiency by way of ferritin levels. 
Objectives and Study End Points 
Primary and secondary objectives were determined a priori. Assessing the 
effect of istradefylline 80 mg/d for 3 and 6 weeks in patients with RLS (primary 
objective) was done by using the proportion of patients undergoing a change 
from baseline in the direction of a therapeutic response to _>1 of the 2 indepen- 
dent variables under study--the IRLSRS or the PLMI. Additional independent 
variables included in the observational nalysis were the PLMI causing arousal 
(PLMIA), the visual analog scale (VAS [a 10-point self-report tool measuring the 
magnitude and intensity of pain score where 0 = no pain and 10 = agonizing 
pain]), and the clincial global impression (CGI), 18 which is a clinician's cale 
measuring treatment response in patients. The CGI consists of the CGI- 
improvement (CGI-I) scale (a 7-point scale ranging from very much improved to 
very much worse, with lower scores indicating improvement in health), and 
the CGI severity of illness scale (a 7-point scale ranging from normal to most 
extremely ill, with higher scores representing severity of illness). The CGI 
assessment tool was used to allow the investigator to evaluate the patients' 
improvement of symptoms during the study, based on the patients' responses. 
Improvement in the CGI-I score was assessed throughout the study as change 
from initial ratings. Polysomnographic evaluation of total sleep time (TST) was 
also performed. 
Assessing the tolerability of istradefylline treatment in patients with RLS 
(secondary objective) was done by accumulating tolerability data. Observations 
were carried out on all patients completing >1 assessment. Patients erved as 
their own controls, with comparisons made against baseline. 
Procedures 
Attended nocturnal polysomnograms (NPSGs) were obtained using a 
35-channel polysomnographic system (Twin, version 3.5a, Grass-Telefactor, 
Rockland, Maryland). Accepted standard criteria were used for acquisition and 
scoring. 19-21 A single adaptation ight preceded the first baseline NPSG. The 
PLMI (average number of PLMs per hour during NPSG-recorded sleep) was 
measured as well as the PLMI A. Sleep architecture was characterized on the 
basis of TST. 
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All existing RLS treatments were discontinued >1 week before study entry. 
Prior to treatment, 3 consecutive NPSGs were performed at 1-week intervals to 
obtain a baseline assessment of the PLMI. After this 2-week baseline assess- 
ment period, patients were instructed to administer a single 80-mg istradefyl- 
line tablet QD with food in the late afternoon or early evening, >2 hours before 
the expected time of symptom onset. Patients were instructed to follow treat- 
ment regimen for 6 weeks. Assessments were repeated after weeks 3 and 6. 
Study drug was discontinued immediately following 6 weeks of treatment. A 
final assessment was conducted 2 weeks after treatment termination. 
Adherence was monitored at each study visit by study site personnel. Pa- 
tients were instructed on the proper use of study drug and the importance of 
recording any new concomitant medications. Drug accountability logs were 
maintained ocumenting pill counts. Patients were required to undergo physical/ 
neurologic examination, vital sign and weight assessments, clinical laboratory 
tests (serum chemistry, hematology, urinalysis), and a 12-lead electrocardio- 
gram (ECG) at each study visit. The clinical investigator (J.D.), who was not 
blinded to the study, performed all assessments, including AE queries, which 
were conducted at each patient visit. Tolerability was evaluated by comparing 
potential AEs reported at designated visits (while receiving study drug) to 
those at baseline. Clinically relevant changes in laboratory data and abnormali- 
ties observed in the ECG were also documented. 
All statistical tests were interpreted as descriptive, except he mean TST, 
which was analyzed using a paired t test (Microsoft Excel 2000, Analysis 
ToolPak, Microsoft Corp., Seattle, Washington). 
RESULTS 
A total of 15 patients (mean [SD] age, 61 [7.1] years; range, 50-69 years) were 
assessed for inclusion in the study. The mean duration of RLS was 18 years. 
Of this number, 6 patients were excluded because they had an AHI _>15, or a 
PLMI <20 at baseline. In addition, 2 patients withdrew consent because of an 
inability to tolerate withdrawal of existing RLS treatments. Because of a concern 
regarding the ability to comply with study protocol, 1 patient was excluded. 
Another patient was excluded for administrative purposes. Therefore, 5 patients 
(all female) were included in the study. 
The demographic and clinical characteristics of the 5 remaining study 
entrants are summarized in Tables I and II. Four of the 5 patients were experi- 
encing severe RLS at study entry based on IRLSRS criteria. The PLMI data col- 
lected across 3 baseline NPSGs were heterogeneous, but generally there was 
moderate to severe elevation in 4 of the 5 patients. 
After treatment, 2 patients had CGI-I scores indicating "much improved" 
along with corresponding reductions in VAS scores. The IRLSRS scores in 
these patients had similarly improved. However, PLMI data remained ifficult 
to interpret because patients erved as their own controls, and the night-to- 
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night variability of this parameter was high. Nevertheless, we observed a 
reduction of the PLMI in 1 patient. Although data for week 8 (washout period) 
were only available for 2 patients, there appeared to be a movement toward a 
return to baseline severity after withdrawal of istradefylline in both of these 
patients. 
As expected, sleep architecture at study entry was uniformly impaired in 
these patients with severe RLS: mean (SD) TST after 3 consecutive pretreat- 
ment NPSGs was 236 (91.9) minutes (17 patient-nights). After 6 weeks of treat- 
ment, mean TST was 246 (103.0) minutes (8 patient-nights). This numeric in- 
crease was not statistically significant. 
Tolerability 
Tolerability was evaluated in all patients who received istradefylline. There 
were no clinically significant changes in tolerability based on AE logs from base- 
line. Istradefylline was well tolerated in this small sample. However, in 2 patients, 
reports of insomnia were considered by the investigator to represent clinical 
worsening from baseline and therefore, thought o be probably associated with 
istradefylline. However, these same patients had been receiving opioid treat- 
ment, and neither esponded to istradefylline treatment (Table I). In both cases, 
insomnia persisted after withdrawal of istradefylline and did not return to base- 
line severity until opioid treatment was reinstated. 
DISCUSSION 
We are not aware of any previous tudy exploring the clinical use of istradefyl- 
line in humans with RLS. In this study, we present evidence of a potential clini- 
cal benefit after 6 weeks of treatment with istradefylline in 3 of 5 patients. 
Istradefylline is an analogue of the stimulant caffeine, which is a nonspecific 
adenosine receptor antagonist. In this study, the A2A-specific antagonist is- 
tradefylline did not significantly improve TST, and it might have potentially 
aggravated the insomnia observed in these RLS patients. This could be related 
to adenosine AzA-receptor interactions. Adenosine agonists elective for the A2A 
receptor (but not for the A 1 receptor) have been found to be somnogenic, 22 and 
therefore, A2A-receptor antagonists such as istradefylline might be expected to 
produce stimulant effects. Although the observed lack of effect on sleep archi- 
tecture and the reported insomnia re of potential clinical significance, they 
might not necessarily predict lack of effectiveness in regard to RLS. Dopa- 
minergic agonists have been found to effectively reduce the PLMI in RLS pa- 
tients even though sleep architecture did not improve. 23-25 
From a practice perspective, patients with severe RLS might require daytime 
doses of dopaminergic agonists because of augmentation. 3 In such cases, the 
sedative effects of dopaminergic drugs could become dose-limiting. Daytime 
administration of istradefylline might be useful as an adjunct o more sedating 
drugs. 
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Study Limitations 
The lack of a parallel control arm, the open design, and the small sample size 
are limitations of this study. In addition, large within-patient variability of the 
PLMI findings made it difficult to interpret polysomnographic data. An observ- 
able effect on the PLMI was evident in only 1 patient. However, this finding was 
discordant with her IRLSRS (Table II); the patient was a white female aged 
69 years who had considerable neuropathic pain in addition to her moderately 
severe RLS. Comorbid chronic pain in this patient might have interfered with 
the ability of the IRLSRS to identify a treatment effect, since this particular at- 
ing scale might be more likely to ascertain the sensory component of RLS. 
Although less heterogeneous, the effects of istradefylline when assessed using 
more subjective indicators uch as IRLSRS and VAS remain difficult to interpret 
without appropriate masking. Two patients withdrew consent prior to the com- 
pletion of the trial for reasons relating to lack of perceived effect, presenting a 
further challenge to the interpretation of the data. The protocol required that 
their prior opioid treatment be discontinued for them to be eligible for participa- 
tion in the study. They exhibited no improvement in the IRLSRS. We suspect 
opioid withdrawal effects might have negatively influenced their response to the 
study drug. However, because these patients had received at least some treat- 
ment, it would have been inappropriate o exclude them from the analysis. 
CONCLUSION 
This pilot study provides preliminary evidence suggesting a potential role for istrade- 
fylline, a prototypic adenosine A2A-receptor antagonist, in the treatment ofRLS. 
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